Nipro Vialex – 26th January 2025
PCI – 7th June 2024
Temax_Krautz

Current Edition

Nasal & Pulmonary Drug Development
Novo Nordisk 20 March 2024, 11:21
Carterra – 24th March 2025

Ginkgo Bioworks, Boehringer Ingelheim partner on breakthrough therapies

Ginkgo Bioworks, a Boston-based biotech working on cell programming and biosecurity, announced this week that it has partnered with Boehringer Ingelheim to work on breakthrough therapies for hard-to-treat diseases.

The two will leverage the Ginkgo metagenomic sequence database, which contains a wealth of structurally unique bioactive molecules, to potentially identify novel treatment targets. 

Under the terms of the agreement, Boehringer Ingelheim will pay Ginkgo an undisclosed amount for upfront research fees. Ginkgo would then be eligible for success-based research and development, regulatory, and commercial milestone payments up to $406 million total, as well as potential future royalty payments. 

Ginkgo Bioworks, established in 2008, was founded by MIT researchers with a mission to “make biology easier to engineer.” In 2022, the company made its largest acquisition yet, buying American biotech Zymergen for $300 million. 

Scott Pharma – 25.03.2025
SMI – 24/03/2025
Chemspec Europe – 27.02.2025
PHARMAP: Mon 14 October 2024, 10.36
FujiFilm Skyscraper: 26th November 2024
Woolcool 26 March 2024, 16:16
Biopharma group 6 March 2024, 09:40
EyeC 18 March 2024, 13:10
L.B. Bohle – 08.04.2025